In 2004, the first randomized, controlled clinical trial with the non-replicable Ad HSV-TK/GCV (AdHSV-TK/GCV) gene therapy was carried out (NCT00005025).87 Since then, Ad-TK vectors have been applied in multiple clinical trials around the world for treating numerous types of solid tumor cancers. Here, TKT is linked to cancer.